- Future Students
- Current Students
- Faculty & Staff
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.
|Title||Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.|
|Publication Type||Journal Article|
|Year of Publication||2008|
|Authors||Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJA|
|Journal||Human molecular genetics|
|Date Published||2008 Dec 15|
|Keywords||Animals, Cell Membrane Permeability, Dose-Response Relationship, Drug, Dystrophin, Gene Expression Regulation, Heart Injuries, Mice, Mice, Inbred C57BL, Mice, Inbred mdx, Morpholines, Morpholinos, Muscle, Skeletal, Muscular Dystrophy, Animal, Oligonucleotides, Antisense, Peptides|
Antisense oligonucleotides (AOs) have the potential to induce functional dystrophin protein expression via exon skipping by restoring in-frame transcripts in the majority of patients suffering from Duchenne muscular dystrophy (DMD). AOs of morpholino phosphoroamidate (PMO) and 2'-O-methyl phosphorothioate RNA (2'Ome RNA) chemistry have been shown to restore dystrophin expression in skeletal muscle but not in heart, following high-dose systemic delivery in murine models of muscular dystrophy (mdx). Exploiting the cell transduction properties of two basic arginine-rich cell penetrating peptides, we demonstrate widespread systemic correction of dystrophin expression in body-wide muscles and cardiac tissue in adult dystrophic mdx mice, with a single low-dose injection of peptide-conjugated PMO AO. This approach was sufficient to restore uniform, high-level dystrophin protein expression in peripheral muscle and cardiac tissue, with robust sarcolemmal relocalization of the dystrophin-associated protein complex and functional improvement in muscle. Peptide-conjugated AOs therefore have significant potential for systemic correction of the DMD phenotype.
|Alternate Journal||Hum. Mol. Genet.|